Artigos de revistas sobre o tema "Hc427"
Siga este link para ver outros tipos de publicações sobre o tema: Hc427.
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 16 melhores artigos de revistas para estudos sobre o assunto "Hc427".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
1
Swartz, Adam, Kendra Congdon, Smita Nair, Qi-Jing Li, James Herndon, Carter Suryadevara, Katherine Riccione et al. "TMOD-14. CONJOINED CLASS I AND II EPITOPES ENHANCE NEOANTIGEN-TARGETED ACTIVE IMMUNOTHERAPY". Neuro-Oncology 23, Supplement_6 (2 de novembro de 2021): vi218. http://dx.doi.org/10.1093/neuonc/noab196.875.
Texto completo da fonteResumo:
Abstract INTRODUCTION Cancer vaccines involve the administration of tumor-associated antigens into the host to generate anti-tumor T cell responses. Glioblastoma (GBM) is a disease with poor prognosis. GBM has a limited number of immunotherapeutic targets due to low mutational load, and is also highly heterogeneous; targeting a single antigen leads to antigen escape and tumor growth. METHODS VMDK mice were subcutaneously implanted with 750,000 SMA560 cells and on days 1 and 8 post implantation, mice were treated with 15 nmol of the universal helper epitope, P30, conjoined to the MHCI-restricted neoepitopes Odc1MHCI-P30 or Topbp1MHCI-P30. Human CD27 (hCD27) transgenic mice were intracranially implanted with CT2A-Odc1, followed by anti-CD27 and 15 nmol of Odc1MHCI-P30. B16.OVA or B16.F10 tumor cells were intracranially implanted in hCD27 mice and received SIINFEKL-P30 or Trp2-P30 conjoined peptides. Tumor growth, survival, or IFNγ secretion of splenic or tumor-infiltrating cells was assessed. RESULTS Unlike Odc1MHCI mixed with P30, conjoined Odc1MHCI-P30 had equivalent immunogenicity and anti-tumor efficacy to that observed with native long Odc1 peptide. Native long peptide of Topbp1 did not elicit an antitumor response, yet Topbp1MHCI-P30 caused an increase in numbers of IFNγ-secreting splenocytes and a decrease in tumor growth and similar to that seen with Odc1MHCI-P30 . Anti-CD27 treatment significantly increased numbers of IFNγ secreting splenocytes in Odc1MHCI-P30 vaccinated hCD27 mice, and the use of anti-CD27 with Odc1MHCI-P30 achieved long-term survival in 90% of tumor bearing hCD27 mice. Anti-CD27 synergized with SIINFEKL-P30 and Trp2-P30 to significantly improve survival after administration of these peptides. CONCLUSIONS Our work shows that poorly immunogenic neoantigens can be conjoined to P30 and used to generate an anti-tumor response in mouse models of GBM, and anti-tumor responses of conjoined peptides can be enhanced with anti-CD27 treatment. Together, these data demonstrate the efficacy of neoantigen vaccines for the treatment of heterogeneous GBM.
2
Forsberg, Eric, Li-Zhen He, Kathleen Borrelli, James Boyer, Lauren Gergel, Catherine Pilsmaker, Sarah Round et al. "Therapeutic efficacy of a fully human anti-CD27 monoclonal antibody in a murine colon carcinoma model (162.23)". Journal of Immunology 188, n.º 1_Supplement (1 de maio de 2012): 162.23. http://dx.doi.org/10.4049/jimmunol.188.supp.162.23.
Texto completo da fonteResumo:
Abstract The costimulatory molecule CD27 is constitutively expressed on the majority of mature T cells, memory B cells, and a portion of NK cells. The interaction of CD27 with its ligand CD70 plays an important role in effector capacity and memory in T cells; in clonal B cell expansion and germinal center formation; and in NK cell cytolytic activity. Agonistic anti-mouse CD27 mAbs have been shown to have potent anti-tumor activity. A panel of fully human antibodies recognizing human CD27 was generated and we have previously shown that our lead clone (1F5) can mediate anti-tumor effects using the BCL1 B-lymphoma line in human CD27-transgenic (hCD27-Tg) mice. In order to further investigate the mechanism of this anti-hCD27 monoclonal and its activity in a therapeutic setting we assessed anti-tumor activity using the CT26 murine colon carcinoma line. CT26 cells were delivered s.c. to hCD27-Tg animals and five doses of 1F5 were delivered to mice i.p. beginning on days 3, 5, or 7. In multiple experiments, tumor growth in mice treated with 1F5 was substantially delayed or prevented compared to that of control-treated mice. When 1F5-treated surviving mice were rechallenged with CT26 cells, without additional anti-CD27 antibody treatment, tumors did not grow in most animals. These data support the continued clinical development of this anti-CD27 mAb to enhance immune responses in cancer therapy. Investigations of immune cell subset depletions and combination therapies are ongoing.
3
Nehbandani, Alireza, Afshin Soltani, Reza Taghdisi Naghab, Amir Dadrasi e Seyyed Majid Alimagham. "Assessing HC27 Soil Database for Modeling Plant Production". International Journal of Plant Production 14, n.º 4 (2 de setembro de 2020): 679–87. http://dx.doi.org/10.1007/s42106-020-00114-4.
Texto completo da fonte
4
Fischione, Piera, Daniele Celli, Davide Pasquali, Gabriel Barajas, Benedetto Di Paolo e Javier L. Lara. "Inside a Beach Drainage System: A Three-Dimensional Modeling". International Journal of Offshore and Polar Engineering 33, n.º 2 (1 de junho de 2023): 196–203. http://dx.doi.org/10.17736/ijope.2023.hc27.
Texto completo da fonte
5
Guillaudeux, Thierry, Yulia Ovechkina, Kurt Lustig e Shawn Iadonato. "Abstract B034: CD27 is a new promising T cell co-stimulatory target for cancer immunotherapy". Cancer Immunology Research 11, n.º 12_Supplement (1 de dezembro de 2023): B034. http://dx.doi.org/10.1158/2326-6074.tumimm23-b034.
Texto completo da fonteResumo:
Abstract Members of the tumor necrosis factor receptor superfamily (TNFRSF) are key co-stimulators of T cells. CD27, a member of the TNFRSF, is expressed only on the surface of lymphocytes, including naive and activated CD4+ and CD8+ T cells as well as NK cells. It enhances T cell activation, proliferation, and differentiation of effector and memory T cells after stimulation with its ligand, CD70. The costimulatory signal of CD27 is mediated via the NFkB pathway but also via the phosphatidylinositol 3 kinase and the protein kinase B pathways. CD27 signaling also influences the innate immune response via direct activation of NK cells and subsequent secretion of interferon-gamma (IFNg). Several published preclinical studies demonstrated that anti-CD27 agonistic monoclonal antibodies can promote T-cell activation and antitumor immunity making CD27 an attractive cancer immunotherapy target. Here we describe the characterization, preclinical development, and selection of our anti-CD27 fully human monoclonal antibody (mAb) lead candidate. We selected this candidate from a library of 147 anti-CD27 mAbs generated after immunization of humanized Trianni® mice with soluble human CD27 extracellular domain (hCD27-ECD). Anti-CD27 mAbs were tested in an accelerated stability study and showed excellent stability parameters for up to 7 days at 4 and 37°C in commonly used formulation buffers. The selected agonist anti-CD27 mAb demonstrated high affinity binding to both human and cynomolgus monkey CD27 and not to mouse CD27. It also demonstrated high specificity against CD27 with no cross-reactivity detected against other members of the TNFRSF. This lead candidate did not block the binding of CD27 natural ligand, CD70 and induced strong NFkB-mediated CD27 signaling in the absence or presence of cross-linking by Fc gamma receptors or secondary cross-linking antibodies. Moreover, this anti-CD27 mAb mediated NFkB activation is significantly potentiated by the addition of a sub-optimal amount of soluble CD70. The anti-CD27 lead mAb induced T cell proliferation and secretion of pro-inflammatory cytokines only in the presence of sub-optimal TCR stimulation in vitro using primary human T cells. It also activated NK cells demonstrated by CD69 expression induction. The anti-CD27 mAb lead candidate showed extended serum half-life in hCD27-KI mice. It also demonstrated a significant antitumor effect as a single agent in human CD27-Knockin mice (hCD27-KI) subcutaneously implanted with MC38 or in NOD-SCID mice subcutaneously implanted with Raji. These preclinical results establish that the selected anti-CD27 mAb is a promising drug candidate and we are actively pursuing its development. Citation Format: Thierry Guillaudeux, Yulia Ovechkina, Kurt Lustig, Shawn Iadonato. CD27 is a new promising T cell co-stimulatory target for cancer immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl):Abstract nr B034.
6
Widdess, Marcus A., H. T. Claude Chan, Christine A. Penfold, C. Ian Mockridge, Tatyana Inzhelevskaya, Hannah J. Metcalfe, Mark S. Cragg e Aymen Al-Shamkhani. "Abstract A26: Tetravalency endows anti-CD27 antibodies with enhanced co-stimulatory activity and anti-tumour immune responses". Cancer Immunology Research 10, n.º 12_Supplement (1 de dezembro de 2022): A26. http://dx.doi.org/10.1158/2326-6074.tumimm22-a26.
Texto completo da fonteResumo:
Abstract Immunostimulatory antibodies targeting co-stimulatory TNFRSF members have shown promise in pre-clinical cancer models, but this has not translated into clinical success, primarily due to lack of efficacy. Oligomerisation of the co-stimulatory molecule CD27 by its trimeric membrane-bound ligand activates NF-κB and AP1 signalling leading to enhanced CD8 T cell responses in both humans and mice. Targeting CD27 with bivalent mAb may lead to sub-optimal receptor oligomerisation and inefficient T cell activation. Here we present a general approach to improve the potency of anti-CD27 mAb. We engineered tetravalent forms of anti-CD27 antibodies targeting both mouse and human CD27 by attaching two additional Fab fragments to the N-terminus of the of the IgG VH domain. These tetravalent mAb had greater avidity to CD27 and were more potent than their bivalent counterparts in stimulating NF-κB activation and T cell proliferation in vitro, with optimal responses requiring antibody crosslinking by FcγRIIb. In addition, confocal microscopy of hCD27-GFP fusion protein expressing Jurkat T cells showed that tetravalent anti-hCD27 mAb triggered receptor clustering more efficiently than the equivalent bivalent mAb, as evidenced by the increased number of receptor clusters on the cell surface. Importantly, tetravalent anti-CD27 mAb induced greater CD8 T cell responses than the bivalent mAb in a vaccination model and was more efficacious in suppressing tumour growth in vivo. This work demonstrates that the agonistic activity of anti-CD27 mAb can be significantly improved by tetravalency and suggest that this approach could be utilised to enhance the therapeutic activity of mAb targeting other members of the TNFRSF. Citation Format: Marcus A Widdess, H. T. Claude Chan, Christine A Penfold, C Ian Mockridge, Tatyana Inzhelevskaya, Hannah J Metcalfe, Mark S Cragg, Aymen Al-Shamkhani. Tetravalency endows anti-CD27 antibodies with enhanced co-stimulatory activity and anti-tumour immune responses [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl):Abstract nr A26.
7
Riccione, Katherine, Luis Sanchez-Perez, Catherine Flores e John Sampson. "Characterization of a human CD27 agonistic monoclonal antibody for use as an agent in glioblastoma therapy (P4411)". Journal of Immunology 190, n.º 1_Supplement (1 de maio de 2013): 205.15. http://dx.doi.org/10.4049/jimmunol.190.supp.205.15.
Texto completo da fonteResumo:
Abstract CD27 is a costimulatory molecule constitutively expressed on naïve T-cells, B-cells, and subsets of NK cells; signaling through CD27 has been shown to promote Th1 polarization, clonal expansion, enhanced survival of effector and memory cells, upregulation of effector molecules, and enhanced cytolytic activity. We are characterizing the use of an agonistic anti-CD27 antibody, CDX1127, as a treatment in a preclinical glioblastoma model in human CD27 transgenic mice. We have shown that in vitro stimulation of isolated T-cells from hCD27+/- mice with CDX1127, in the context of TCR signaling, leads to increased proliferation, decreased apoptosis, and increased secretion of IFN-γ and TNF-α, corroborating its agonistic activity. Furthermore, we have analyzed the efficacy of CDX1127 as a monotherapy in a mouse glioblastoma model as well as an adjuvant in a total tumor RNA dendritic cell vaccine.
8
Yang, Xiaoyong, e Tan Jin. "Fractal calculation method of friction parameters: Surface morphology and load of galvanized sheet". Open Physics 19, n.º 1 (1 de janeiro de 2021): 375–82. http://dx.doi.org/10.1515/phys-2021-0042.
Texto completo da fonteResumo:
Abstract In the forming process of galvanized sheet, the friction between the die and the blank often causes the zinc coating of galvanized sheet to peel off, scratch, and crack. The aim of this study is to evaluate and calculate the fractal characteristics of the surface morphology of galvanized sheet and the effect of pressure on the interfacial friction behavior. Two steel plates, GA and GI, produced by Shanghai Baosteel Company, were used as materials to conduct tribological experiments, measure the surface profile and three-dimensional shape of the galvanized sheet, and calculate the fractal dimension and fractal roughness parameters. According to the analysis results of friction surface damage of galvanized sheet, the damage failure parameters of galvanized sheet are calculated. On this basis, according to the adhesive friction theory, the total surface friction value of galvanized sheet is obtained, and the fractal calculation model of galvanized sheet friction is established. The simulation results show that the galvanized sheet has fractal characteristics. The average values of fractal dimension and scale factor of SP781BQ alloy hot-dip galvanized sheet are 1.52 and 0.23 µm, respectively. The average fractal dimension and scale coefficient of HC420/780DPD + Z hot-dip galvanized sheet are 1.60 and 0.11 µm, respectively. The friction coefficient calculated by the proposed method is consistent with the theoretical value, and the error is less than 10%, which proves the accuracy and feasibility of the friction fractal calculation method.
9
Kheloufi, Farid, Isabelle Poizot-Martin, Rodolphe Garraffo, Aude Tavenard, Sylvie Quaranta, Alain Renault, Thibault Lavrut et al. "ITPA deficiency and ribavirin level are still predictive of anaemia in HCV–HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study)". Antiviral therapy 22, n.º 6 (2016): 461–69. http://dx.doi.org/10.3851/imp3074.
Texto completo da fonte
10
Poizot-Martin, Isabelle, Eric Bellissant, Rodolphe Garraffo, Philippe Colson, Lionel Piroth, Caroline Solas, Alain Renault et al. "Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study". HIV Clinical Trials 17, n.º 2 (11 de fevereiro de 2016): 63–71. http://dx.doi.org/10.1080/15284336.2015.1135553.
Texto completo da fonte
11
He, Li-Zhen, Larry Thomas, Jeffery Weidlick, Laura Vitale, Tom O'Neill, Naseem Prostak, Karuna Sundarapandiyan et al. "Development of a Human Anti-CD27 Antibody with Efficacy in Lymphoma and Leukemia Models by Two Distinct Mechanisms". Blood 118, n.º 21 (18 de novembro de 2011): 2861. http://dx.doi.org/10.1182/blood.v118.21.2861.2861.
Texto completo da fonteResumo:
Abstract Abstract 2861 CD27, a lymphoid cell-specific TNFR superfamily member, is constitutively expressed on the majority of T cells, some NK cells and memory B cells. Through interaction with its ligand CD70, CD27 transduces a co-stimulatory signal promoting T cell and NK cell activation and cytotoxicity. In addition, CD27 is also expressed on many lymphoid-originated hematological neoplastic cells, such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia, thus being a potential direct target for antibody therapy. To generate potential antibodies for clinical development, we immunized human Ig transgenic mice and developed a panel of CD27 specific human mAbs. Clone 1F5 was identified as a lead based on its high affinity to both human and monkey CD27, enhanced co-stimulation of T cells, and ADCC of CD27-expressing lymphoblastic cell lines. Using SCID mice challenged with CD27-expressing human lymphoid cell lines, we demonstrated that 1F5 mediates conventional antibody effector function. Compared to human IgG1 isotype control (huIgG1), 1F5 at doses ranging 33 μg – 500 μg (x 6) significantly delayed the growth of Burkitt's lymphoma Raji even when administration was initiated 1 week after tumor inoculation. Similar anti-tumor activity was observed against other CD27-expressing tumor lines including, Daudi and T-originated acute lymphoblastic leukemia CCRF-CEM. In order to investigate 1F5 in vivo agonistic activities and T cell-mediated tumor eradication, a human CD27 transgenic mouse model (hCD27-Tg) was generated and backcrossed onto C57BL/6 and BALB/c backgrounds. The expression profile and regulation of the human CD27 transgene driven by its own promoter were similar to that observed with endogenous mouse CD27. In addition to enhancing T cell responses when combined with vaccination, 1F5 treatment was highly effective against syngeneic mouse tumors including lymphoma BCL1 (BALB/c) and thymoma EL4-derived E.G7 (C57BL/6). For the BCL1 model, various dose levels of 1F5 mAb were delivered to mice intraperitoneally on days 3, 5, 7, 9 and 11 after i.v. administration of 107 BCL1 cells to huCD27 Tg and control animals. Controls including hCD27-Tg mice treated with saline or isotype control, or WT mice treated with 1F5 all performed consistently, leading to 50% survival approximately 23 days after tumor challenge. Treatment of mice with mAb, 1F5 substantially improved the 50% survival in a dose dependent fashion to >70 days post tumor challenge at the higher dose levels. Based on the promising efficacy data with anti-CD27 mAb 1F5 in immunocompromised and immunocompetent lymphoma models, a clinical grade product, referred to as CDX-1127 was manufactured and tested for safety. To assess the potential for 1F5 to mediate lymphocyte activation, we investigated its ability to induce proliferation and cytokine release from human PBMC or purified T cell cultures. Consistent with the known biology of CD27 we demonstrated the 1F5 mAb does not lead to direct activation of lymphocytes in the absence of additional signals. However, combining 1F5 with suboptimal levels of T cell receptor stimulation using anti-CD3 mAb (OKT3) was shown to enhance proliferation of human T cells. Two studies were performed using cynomolgus macaques. There were no CDX-1127 related mortalities or changes noted in the clinical condition, food appetence, body weights and body temperature, ophthalmic, electrocardiographic and clinical pathology assessments, organ weights and bone marrow assessments. In addition, there were no major differences in the percentage of lymphocyte populations between control and CDX-1127 treated animals at the end of the study demonstrating that the antibody did not significantly deplete normal CD27-expresssing cells. Based on the pre-clinical studies we are planning a Phase 1 clinical trial of CDX-1127 in patients with hematological malignancies and selected solid tumors. The trial is designed with separate arms to independently assess the safety and activity of CDX-1127 in hematologic malignancies, in which the antibody may act through multiple mechanisms, and in solid tumors where it would be fully dependent on indirect immune mechanisms. Disclosures: He: Celldex Therapeutics, Inc.: Employment. Thomas:Celldex Therapeutics, Inc.: Employment. Weidlick:Celldex Therapeutics, Inc.: Employment. Vitale:Celldex Therapeutics, Inc.: Employment. O'Neill:Celldex Therapeutics, Inc.: Employment. Prostak:Celldex Therapeutics, Inc.: Employment. Sundarapandiyan:Celldex Therapeutics, Inc.: Employment. Marsh:Celldex Therapeutics, Inc.: Employment. Yellin:Celldex Therapeutics, Inc.: Employment. Davis:Celldex Therapeutics, Inc.: Employment. Keler:Celldex Therapeutics, Inc.: Employment.
12
Su, Harvey Yu-Li, Chang-Ting Lin, Shih-Yu Huang, Yi-Hua Chen e Chung-Wen Kuo. "Abstract 3679: Development and validation of prognostic signatures comprising neutrophil-specific long non-coding RNAs (LncRNAs) for predicting survival in urothelial carcinoma". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 3679. http://dx.doi.org/10.1158/1538-7445.am2024-3679.
Texto completo da fonteResumo:
Abstract Background: Tumor-associated neutrophils profoundly influence the tumor immune microenvironment (TME), impacting urothelial carcinoma (UC) progression, metastasis, and survival. Long non-coding RNAs (lncRNAs) have emerged as critical players in cancer biology. Recognizing neutrophils as influential contributors to tumor biology, our study aimed to explore neutrophil-specific lncRNAs and evaluate their prognostic significance in UC. Methods: In the GSE24890 dataset, 46 lncRNAs were identified with elevated expression in neutrophils compared to other immune cells, thus designating them as neutrophil-specific lncRNAs. To establish a tailored prognostic model, the TCGA BLCA dataset served as the internal training set. Candidate lncRNAs underwent filtration and selection through univariate Cox regression analysis, followed by the construction of a risk score employing LASSO and multivariate Cox regression algorithms. We used IMVigor210 dataset as external validation for this lncRNA model. Results: Ten lncRNAs exhibiting correlation with overall survival (OS) were initially identified through univariate Cox regression. Following LASSO regression and subsequent multivariate Cox regression analysis, a refined set of 9 lncRNAs was selected to construct the risk model, represented by the formula: Risk score = (-0.096 × FAM13A-AS1 expression level) + (0.157 × FAM27C expression level) + (-0.294 × HCG27 expression level) + (-0.037 × HOTAIRM1 expression level) + (-0.137 × LINC-PINT expression level) + (-0.279 × LINC00612 expression level) + (-0.058 × LINC00967 expression level) + (0.187 × LINC01018 expression level) + (-0.288 × LINC01138 expression level). Kaplan-Meier survival analysis of the BLCA cohort revealed that patients in the high-risk group experienced significantly worse OS compared to those in the low-risk group (p < 0.001). The area under the curve (AUC) values at 1, 3, and 5 years were 0.66, 0.67, and 0.66, respectively. In the multivariate Cox regression model, the risk score remained an independent prognostic factor (p < 0.001; HR 2.5; 95% CI 1.91-3.30). The validity of the risk score was further confirmed in the IMVigor210 dataset, demonstrating discriminative predictive ability for OS between high- and low-risk groups (p = 0.027). Conclusions: This study underscores the interplay between neutrophils and lncRNAs in UC. Neutrophil-related lncRNAs identified may serve as promising therapeutic targets and prognostic markers for UC. Citation Format: Harvey Yu-Li Su, Chang-Ting Lin, Shih-Yu Huang, Yi-Hua Chen, Chung-Wen Kuo. Development and validation of prognostic signatures comprising neutrophil-specific long non-coding RNAs (LncRNAs) for predicting survival in urothelial carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3679.
13
Wasiuk, Anna, Jeff Weidlick, Crystal Sisson, Jenifer Widger, Andrea Crocker, Laura Vitale, Henry C. Marsh, Tibor Keler e Li-Zhen He. "Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice". Cancer Immunology, Immunotherapy, 24 de maio de 2021. http://dx.doi.org/10.1007/s00262-021-02958-9.
Texto completo da fonteResumo:
AbstractCyclophosphamide plus fludarabine (C/F) are currently used to improve the expansion and effectiveness of adoptive cell therapy (ACT). However, these chemotherapeutics cause pan-leukopenia and adverse events, suggesting that safer and more effective conditioning treatments are needed to improve ACT outcomes. Previously, we reported that varlilumab, a CD27-targeting antibody, mediates Treg -preferential T cell depletion, CD8-T cell dominant costimulation, and systemic immune activation in hCD27 transgenic mice and cancer patients. We reasoned that the activities induced by varlilumab may provide an effective conditioning regimen for ACT. Varlilumab pretreatment of hCD27+/+mCD27 − /− mice resulted in prominent proliferation of transferred T cells isolated from wild-type mice. These studies uncovered a critical role for CD27 signaling for the expansion of transferred T cells, as transfer of T cells from CD27 deficient mice or treatment with a CD70 blocking antibody greatly reduced their proliferation. In this model, varlilumab depletes endogenous hCD27+/+ T cells and blocks their subsequent access to CD70, allowing for more CD70 costimulation available to the mCD27+/+ transferred T cells. CD27-targeted depletion led to a greater expansion of transferred T cells compared to C/F conditioning and resulted in longer median survival and more cures than C/F conditioning in the E.G7 tumor model receiving OT-I cell therapy. We propose that translation of this work could be achieved through engineering of T cells for ACT to abrogate varlilumab binding but preserve CD70 ligation. Thus, varlilumab could be an option to chemotherapy as a conditioning regimen for ACT.
14
"Cause Analysis and Corrosion Resistance Improvement of HC420 / 780DP Coating Coupon". Foreign Language Science and Technology Journal Database Engineering Technology, 2 de novembro de 2020. http://dx.doi.org/10.47939/et.v1i2.46.
Texto completo da fonte
15
Zhang, Jing-yi, Yi Jiang, Li-jie Wei, Xuan Zhou, Sheng-lan Zhu, Hui-ting Zhang, Yu-ting Chen et al. "LncRNA HCG27 Promotes Glucose Uptake Ability of HUVECs by MiR-378a-3p/MAPK1 Pathway". Current Medical Science, 5 de julho de 2023. http://dx.doi.org/10.1007/s11596-023-2738-1.
Texto completo da fonte
16
Yang, Yuan, Wu-Yang Zhang, Yao Zhang, Shuying Li, Teris Cheung, Dexing Zhang, Todd Jackson, Fan He e Yu-Tao Xiang. "Structure of Hypomanic Symptoms in Adolescents With Bipolar Disorders: A Network Approach". Frontiers in Psychiatry 13 (18 de abril de 2022). http://dx.doi.org/10.3389/fpsyt.2022.844699.
Texto completo da fonteResumo:
BackgroundBipolar disorders (BD) are severe mental illnesses that are often misdiagnosed or under-diagnosed. The self-report 33-item Hypomania Checklist (HCL-33) and the 33-item Hypomania Checklist – external assessment (HCL-33-EA) are well-validated scales for BD symptom detection. This study compared the network structure, central symptoms, and network stability of hypomanic symptoms measured by the HCL-33 vs. the HCL-33-EA.MethodsThis cross-sectional study was conducted from January to December 2019. Adolescents (aged between 12 and 18 years) with BD were recruited from the outpatient department of Child Psychiatry, First Affiliated Hospital of Zhengzhou University. All participants were asked to complete the HCL-33, and their caregivers completed the HCL-33-EA. Network analyses were conducted.ResultsA total of 215 adolescents with BD and their family caregivers were recruited. Node HCL17 (“talk more,” node strength = 4.044) was the most central symptom in the HCL-33 network, followed by node HCL2 (“more energetic,” node strength = 3.822), and HCL18 (“think faster,” node strength = 3.801). For the HCL-33-EA network model, node HCL27 (“more optimistic,” node strength = 3.867) was the most central node, followed by node HCL18 (“think faster,” node strength = 3.077), and HCL17 (“talk more,” node strength = 2.998). In the network comparison test, there was no significant difference at the levels of network structure (M = 0.946, P = 0.931), global strength (S: 5.174, P = 0.274), or each specific edge (all P’s > 0.05 after Holm–Bonferroni corrections) between HCL-33 and HCL-33-EA items. Network stabilities for both models were acceptable.ConclusionThe nodes “talk more” and “think faster” acted as central symptoms in BD symptom network models based on the HCL-33 and HCL-33-EA. Although the most prominent central symptom differed between the two models (“talk more” in HCL-33 vs. “more optimistic” in HCL-33-EA model), networks based on each measure were highly similar and underscored similarities in BD symptom relations perceived by adolescents and their caregivers. This research provides foundations for future studies with larger sample sizes toward improving the accuracy and robustness of observed network structures.